Information for Prescribers of Prescription Drugs Provided Pursuant to Colorado HB 19-1131 and Connecticut HB 6669

Vaccine Products

Marketed Prescription Drug

BEYFORTUS® (50 mg/0.5 mL dose) Syringe BEYFORTUS® (100 mg/mL dose) Syringe Flublok® Trivalent (0.5 mL dose) Syringe Fluzone® High-Dose Trivalent (0.5 mL dose) Syringe Fluzone® Trivalent (0.5 mL dose) Syringe Fluzone® Trivalent (0.5 mL dose) 5 mL Vial MenQuadfi® (0.5 mL dose) Vial MenQuadfi® (0.5 mL dose) Vial Pentacel® (0.5 mL dose) Vial PAXELIS® (0.5 mL dose) Syringe VAXELIS® (0.5 mL dose) Vial

WAC* Price

\$ 2,780.66 per 5 single-dose syringes
\$ 2,780.66 per 5 single-dose syringes
\$ 726.13 per 10 single-dose syringes
\$ 199.29 per 10 single-dose syringes
\$ 185.48 per multi-dose vial
\$ 856.11 per 5 single-dose vials
\$ 1,712.22 per 10 single-dose vials
\$ 581.56 per 5-dose vial package
\$ 1,522.05 per 10 single-dose vials

Below please find as applicable three generic prescription drugs**

No generics applicable to the above prescription drugs

Your patients' out of pocket cost may be different

Information on the variation efficacy of the legend (prescribed) drug marketed to different racial and ethnic groups, if such information is available, can be found in the drug's FDA approved Prescribing Information document which can be accessed at https://www.sanofi.us/en/products-and-resources/vaccines.

*Wholesale Acquisition Cost (WAC) as published by FDB represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to FDB by the manufacturer. WAC does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price. FDB does not perform any independent investigation or analysis of actual transaction prices for purposes of reporting WAC. FDB relies on manufacturers to report or otherwise make available the values for the WAC.

> For more information about First Databank's drug pricing policy, visit https://www.fdbhealth.com/drug-pricing-policy

**The USC (Uniform System of Classification) Therapeutic Classification schema was used to determine similar generic drugs. The HCFA Drug Category of "Non-Innovator Multi-source" as supplied on the CMS (formerly HCFA) quarterly update was used to determine the generic status of the drug products. This list does not imply that the generic prescription drugs on this form are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.

Source: AnalySource® 03/27/2025 as reprinted with permission by First Databank, Inc. All rights reserved. ©2025